Fixes Book Closure For AGM
As per the attached letter27-05-2017
Updates
Zydus receives final approval from the USFDA for Acamprosate Calcium Delayed-Release Tablets27-05-2017
Zydus Cadila gets USFDA nod for anti-histamine drug
Drug firm Zydus Cadila today said it has received approval from the US health regulator to market anti-histamine Cyproheptadine Hydrochloride tablets in the US market. The company has received...23-05-2017
Updates on Amalgamation/ Merger / Demerger
Hon'ble National Company Law Tribunal, Bench at Ahmedabad has approved the Scheme of Arrangement between Cadila Healthcare Limited and Zydus Healthcare Limited and their respective shareholders and creditors vide order dated May 18, 2017.19-05-2017
Post Results Conference Call With Investors / Analysts
We inform that the Company will declare its Financial Results for Q4 2016-17 (January-March 2017) on May 27, 2017. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company will hold post results Q & A session through teleconference with investors/analysts on May 27, 2017 at 6.00 p.m. to discuss the financial performance of the Company for the quarter ended on March...18-05-2017
Press Release
Zydus wins Federal Circuit Appeal in generic version of Lialda (Mesalamine).10-05-2017
Zydus Cadila gets final USFDA nod for Budesonide Capsules
Cadila Healthcare (Zydus Cadila) on Friday informed that the company has received final approval from the US regulator, US Food and Drug Administration (USFDA) to market Budesonide Capsules in 3 mg...05-05-2017